Partners herald new cancer immunotherapy company (Article)

May 5 / 2015

Ottawa/Hamilton – The Ottawa Hospital, the Children’s Hospital of Eastern Ontario (CHEO), the University of Ottawa (uOttawa) and McMaster University congratulate its researchers on forming Turnstone Biologics Inc., a biotechnology company focused on developing new treatments for cancer that harness the patient’s own immune system. The company’s creation was announced earlier today by the Fight Against Cancer Innovation Trust (FACIT), an independent business trust established by the Ontario Institute for Cancer Research (OICR).

Turnstone combines breakthrough discoveries on cancer-fighting (oncolytic) viruses and vaccines from three Ontario researchers who have worked together more than 15 years: Dr. John Bell (from The Ottawa Hospital and uOttawa), Dr. David Stojdl (from CHEO and uOttawa) and Dr. Brian Lichty (from McMaster University).

“By combining oncolytic viruses and vaccines together, we hope to be able to generate powerful direct tumour destruction, as well as a long-lasting immune response to keep the tumour from coming back,” said Dr. Stojdl.

Read full story Back To News